Endogenous Retroviruses in Acute Myeloid Leukemia

Leukemia, Myeloid Clinical Trial

— ERVAL  

Official title:

Human Endogenous Retroviruses in Acute Myeloid Leukemia: Expression and Immune Impact

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04406207
• Other study ID #: 69HCL19_0851
• Status: Withdrawn
• Start date: June 1, 2020
• Est. completion date: January 6, 2022

Study information

• Verified date: August 2022
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for numerous malignant hematologic diseases. Despite recent advances in the field, relapse rates are still high and the first cause of death. The identification of new relevant therapeutic targets is therefore urgently needed.

Human endogenous retroviruses (HERVs) are accounting for 8% of the human genome. While silenced at the steady state (mainly by methylation mechanisms), HERVs reactivations have been described in different conditions such as auto-immune diseases or cancer, leading to an innate and adaptive immune response. Several questions are raised in the field of hematology where few data are available, and the exact role of HERVs in these diseases is still to define.

Our team is currently working on the role of HERVs in different types of cancer. We developed a bioinformatics approach to identify overexpressed HERVs from RNAseq data. We also developed in vitro assays to assess the immunogenicity of different peptides from HERVs open reading frames and showed that several epitopes shared among different HERVs can induce a specific CD8+ T cell response. More recently, we have analyzed 151 acute myeloid leukemia (AML) RNAseq data from TCGA and identified multiple overexpressed HERVs in this disease. Immunogenicity test are currently ongoing with patient's blood at diagnosis.

The main objective of this part of our project is to analyze the establishment of a HERVs-specific CD8+ T cell response participating in graft-versus-leukemia effect after HSCT for AML patients. Secondary objectives are to analyze relations between this response and different clinical factors such as the onset of GVHD or relapse.

Peripheral blood mononuclear cells (PBMCs) from AML patients will be extracted and frozen at different time point: diagnosis, complete remission (pre-HSCT) and after HSCT (M3, M6 and M12). This prospective protocol is currently ongoing at the Centre Hospitalier Lyon Sud, with around 30 samples already available.

After having selected relevant HERVs, specific dextramers identified by DNA barcode will be synthesized. These dextramers allowing the identification of specific T cell responses directed against up to 1000 epitopes, we will be able to screen specific T cells directed against HERVs overexpressed in AML for most common HLA. Dextramer staining will be performed on PBMCs after thawing. Positive cells will be sorted by flow cytometry and DNA will be expanded by PCR before performing sequencing, allowing the identification of specific sequences by its unique DNA barcode.

The analyze of HERVs-specific CD8+ T cell responses after HSCT will allow us to better define HERVs role in the onset of graft-versus-leukemia effect. A specific T cell response without GvHD will define the relevance of such peptides as tumor specific antigens.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 6, 2022
• Est. primary completion date: January 6, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Acute myeloid leukemia (all subtypes)

• Stem cell transplantation indication

• Non opposition to the study

Exclusion Criteria:

• Intensive care unit at diagnosis

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Other:
• Demonstration of T cell responses
Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients. The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HERVs-specific CD8+ T cells responses	HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.	Day 0
Primary	HERVs-specific CD8+ T cells responses	HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.	At remission <- Day 0 + 1 month
Primary	HERVs-specific CD8+ T cells responses	HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.	Before transplant <- Day 0 + 3 month
Primary	HERVs-specific CD8+ T cells responses	HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.	1 month
Primary	HERVs-specific CD8+ T cells responses	HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.	3 months
Primary	HERVs-specific CD8+ T cells responses	HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.	6 months
Primary	HERVs-specific CD8+ T cells responses	HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.	12 months
Primary	HERVs-specific CD8+ T cells responses	HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.	At relapse: up to 6 month after day 0